Raltegravir (MK-0518, Isentress): Basics
- An Overview of Isentress (Raltegravir, MK-0518) (September 13, 2012)
From AIDSinfo
- Isentress (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- FDA Approve U.S. Pediatric Dose for Raltegravir (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Raltegravir (Isentress) (January 13, 2012)
To read PDF, click here.
From AIDS InfoNet
- Merck Lowers Price of Isentress Drug for State AIDS Programs (January 12, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FDA Says Merck's HIV Drug Gets Generic Threat (January 11, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FAQs About Isentress (Raltegravir) (January 4, 2012)
From The Body's "Ask the Experts" Forums
- Isentress (Raltegravir): Pediatric Dosing Recommendations and 2 Chewable Tablet Formulations for Pediatric Dosing (December 21, 2011)
From U.S. Food and Drug Administration
- Patient Information About Isentress (Raltegravir, MK-0518) (PDF) (December 2011)
Prescribing information.
From Merck & Co., Inc.
- Isentress (Raltegravir, MK-0518) Patient Product Information (PDF) (December 2011)
Patient information leaflet.
From Merck & Co., Inc.
 Isentress (Raltegravir) Package Insert Updated (November 3, 2011)
From U.S. Food and Drug Administration
- Merck Announces Expanded Co-Pay Assistance Program for Isentress (Raltegravir) (October 22, 2010)
Enhanced program provides assistance to people living with HIV-1 who are privately insured and have out-of-pocket co-pays.
From Merck & Co., Inc.
- Details of Merck's ADAP Pricing Agreement: Isentress, Crixivan Costs Affected (May 5, 2010)
Price freeze of Isentress (Raltegravir) tablets for ADAPs through 2013 and acceleration of rebate payments to states among important initiatives highlighted.
From National Alliance of State and Territorial AIDS Directors
- AIDS Healthcare Foundation Keeps Up Pressure in Protests Against Merck's HIV Pricing (April 8, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FDA Approves Expanded Use of HIV Drug (July 10, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- HIV/AIDS Update: Isentress (Raltegravir) Indication Extended for the Treatment of HIV-1 Infection in Treatment-Naive Patients (July 9, 2009)
From U.S. Food and Drug Administration
- HIV/AIDS Update: Traditional Approval of Isentress (raltegravir) (February 5, 2009)
From U.S. Food and Drug Administration
- Comparing Two Integrase Inhibitors (September/October 2008)
The first head-to-head study comparing raltegravir and elvitegravir.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Letter Sent by Merck to the Fair Pricing Coalition Announcing ADAP Price Freeze of Isentress (PDF) (August 1, 2008)
From Merck & Co., Inc.
- Isentress (Raltegravir) (January 8, 2008)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Mr. Sharp Goes to Washington (November/December 2007)
Advocating for a new drug before the FDA.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
|
Advertisement
|
Email
Glossary
